Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hemlibra

- PMLiVE

FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

Agency is due to make a decision for the approval by May 2021

Roche Basel Switzerland

New data reinforces safety profile of Roche’s Hemlibra

Blockbuster haemophilia A treatment presents a strong challenge to rival drugs

- PMLiVE

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Halts three studies because of safety concerns

- PMLiVE

Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price

Vowed to break patent if company goes ahead with proposed price

Roche Basel Switzerland

Roche to close $4.3bn Spark deal after FTC clearance

Comes on the heels of CMA green light

- PMLiVE

Sangamo steps up BioMarin chase with haemophilia gene therapy data

Updated results presented at ASH 2019

Roche Basel Switzerland

Roche reports continued growth in Q3, despite biosimilar competition

Spark acquisition expected to complete this year

- PMLiVE

Gilead poaches Genentech-exec Merdad Parsey for its new CMO

Company also files potential blockbuster filgotinib in Japan

- PMLiVE

Genentech agrees trade secret theft settlement with Taiwan’s JHL

Three ex-Genetech workers pleaded not guilty to criminal theft charges

- PMLiVE

Roche’s Hemlibra scores broader NHS funding

Expands to around 2,000 patients in England

- PMLiVE

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Targeting largest family of proteins in cell membranes

- PMLiVE

ACPs to lead gene therapies in haemophilia market growth

New therapies to hit existing players

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links